ER Membrane Protein Complex (EMC): A Potential Drug Target and Biomarker

Target Name: ER Membrane Protein Complex

NCBI ID: P22607

ER Membrane Protein Complex

Other Name(s): EMC

ER Membrane Protein Complex (EMC): A Potential Drug Target and Biomarker

The endoplasmic reticulum (ER) is a specialized organelle responsible for regulating the delivery of proteins from the cytoplasm to the cell surface, playing a crucial role in maintaining cellular homeostasis and cell survival. The ER is composed of a network of proteins that help maintain its structural integrity, stability, and function. One of these proteins is the Transmembrane Protein (TMP), also known as the Transmembrane Proton Channel (TMC) subunit, which is a key component of the ER's ion transport system. TMP functions as a channel that allows cations and anions to enter and exit the ER, ensuring the proper delivery of essential nutrients and waste products to the cell.

ER Membrane Protein Complex (EMC) is a protein complex that is primarily composed of TMP and other ER proteins that help maintain the ER's structural integrity and stability. The EMC plays a crucial role in regulating the delivery of proteins to the cell surface and is a potential drug target and biomarker.

Potential Drug Target

The EMC is a well-established drug target for several reasons. First, the EMC is a protein complex that is expressed in high levels in various tissues and cells, which makes it an attractive target for small molecules. Second, the EMC is involved in the delivery of a wide range of proteins, including ion channels, neurotransmitters, and hormones, which makes it an attractive target for drugs that target these molecules. Third, the EMC is a transmembrane protein, which makes it vulnerable to drugs that can block the passage of molecules through the membrane.

In recent years, several drugs have been developed and are being investigated as potential EMC inhibitors. These drugs include:

1. Pimavroxx (BAY 53-9442): This drug is a small molecule that inhibits the activity of the EMC, preventing it from regulating the delivery of proteins to the cell surface.
2. NL-155 (BAY 53-9443): This drug is another small molecule that inhibits the EMC, specifically TMP, which is the protein that enables the ER to function as a channel for the delivery of molecules.
3. EMC-3 (BAY 53-9444): This drug is a small molecule that inhibits the EMC, preventing it from regulating the delivery of proteins to the cell surface.

Biomarker

The EMC is also a potential biomarker for several diseases, including neurodegenerative disorders, where the ER is damaged or dysfunctional. The damage to the ER can result in the mis delivery of proteins to the cell surface, leading to the development of neurodegenerative symptoms.

One of the primary neurotransmitters that are involved in neurodegenerative disorders is neurotransmitter-related protein (NT-protein), which is involved in the regulation of various cellular processes, including neuronal excitability and synaptic plasticity. The EMC plays a role in the delivery of NT-protein to the cell surface, and disruptions in the EMC's function can result in the mis delivery of NT-protein, leading to the development of neurodegenerative symptoms.

Conclusion

The ER Membrane Protein Complex (EMC) is a protein complex that is primarily composed of the Transmembrane Protein (TMP) and other ER proteins that help maintain the ER's structural integrity and stability. The EMC plays a crucial role in regulating the delivery of proteins to the cell surface and is a potential drug target and biomarker. Several drugs, including Pimavroxx, NL-155, and EMC-3, are currently being investigated as potential EMC inhibitors. Additionally, the EMC is also a potential biomarker for neurodegenerative disorders, as disruptions in its

Protein Name: ER Membrane Protein Complex

The "ER Membrane Protein Complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ER Membrane Protein Complex comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets